Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Systems biology of antioxidants.
Andriantsitohaina R, Duluc L, García-Rodríguez JC, Gil-del Valle L, Guevara-Garcia M, Simard G, Soleti R, Su DF, Velásquez-Pérez L, Wilson JX, Laher I. Andriantsitohaina R, et al. Clin Sci (Lond). 2012 Aug 1;123(3):173-92. doi: 10.1042/CS20110643. Clin Sci (Lond). 2012. PMID: 22494160 Free article. Review.
Oxidative stress as a cofactor in spinocerebellar ataxia type 2.
Guevara-García M, Gil-del Valle L, Velásquez-Pérez L, García-Rodríguez JC. Guevara-García M, et al. Redox Rep. 2012;17(2):84-9. doi: 10.1179/1351000212Y.0000000005. Redox Rep. 2012. PMID: 22564351 Free PMC article. Review.
A comprehensive review of spinocerebellar ataxia type 2 in Cuba.
Velázquez-Pérez L, Rodríguez-Labrada R, García-Rodríguez JC, Almaguer-Mederos LE, Cruz-Mariño T, Laffita-Mesa JM. Velázquez-Pérez L, et al. Cerebellum. 2011 Jun;10(2):184-98. doi: 10.1007/s12311-011-0265-2. Cerebellum. 2011. PMID: 21399888 Review.
Erythropoietin in Spinocerebellar Ataxia Type 2: Feasibility and Proof-of-Principle Issues from a Randomized Controlled Study.
Rodriguez-Labrada R, Ortega-Sanchez R, Hernández Casaña P, Santos Morales O, Padrón-Estupiñan MDC, Batista-Nuñez M, Jiménez Rodríguez D, Canales-Ochoa N, Peña Acosta A, Medrano Montero J, Labrada Aguilera PE, Estupiñán Rodriguez A, Vazquez-Mojena Y, Almaguer Gotay D, Aymed-García J, García-García I, Torres Vega R, Viada González C, Valenzuela Silva CM, Silva Ricardo Y, Columbié Ximelis J, Tribin Rivero K, Valle Cabrera R, García-Rodriguez JC, Crombet Ramos T, Amaro-González D, Rodriguez-Obaya T, Velázquez-Pérez L. Rodriguez-Labrada R, et al. Among authors: garcia rodriguez jc. Mov Disord. 2022 Jul;37(7):1516-1525. doi: 10.1002/mds.29045. Epub 2022 May 23. Mov Disord. 2022. PMID: 35607776 Clinical Trial.
Oral zinc sulphate supplementation for six months in SCA2 patients: a randomized, double-blind, placebo-controlled trial.
Velázquez-Pérez L, Rodríguez-Chanfrau J, García-Rodríguez JC, Sánchez-Cruz G, Aguilera-Rodríguez R, Rodríguez-Labrada R, Rodríguez-Díaz JC, Canales-Ochoa N, Gotay DA, Almaguer Mederos LE, Laffita Mesa JM, Porto-Verdecia M, Triana CG, Pupo NR, Batista IH, López-Hernandez OD, Polanco ID, Novas AJ. Velázquez-Pérez L, et al. Neurochem Res. 2011 Oct;36(10):1793-800. doi: 10.1007/s11064-011-0496-0. Epub 2011 May 12. Neurochem Res. 2011. PMID: 21562746 Clinical Trial.
Nasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers: a randomized, parallel, open-label safety study.
Santos-Morales O, Díaz-Machado A, Jiménez-Rodríguez D, Pomares-Iturralde Y, Festary-Casanovas T, González-Delgado CA, Pérez-Rodríguez S, Alfonso-Muñoz E, Viada-González C, Piedra-Sierra P, García-García I, Amaro-González D; NeuroEPO Study Group; García-Rodríguez JC, Sosa-Testé I, Lagarto-Parra A, Barrero-Viera L, David-Baldo M, Tamayo-Rodríguez M, Rivero-Vázquez I, González-Gamiz G, Martín-Trujillo A, Rodríguez-Fernández Y, Ledo-de la Luz AA, Álvarez-Delgado M, Howland-Álvarez I, Cruz-Gómez Y. Santos-Morales O, et al. Among authors: garcia rodriguez jc. BMC Neurol. 2017 Jul 4;17(1):129. doi: 10.1186/s12883-017-0908-0. BMC Neurol. 2017. PMID: 28676085 Free PMC article. Clinical Trial.
Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ₂₅₋₃₅ non-transgenic mouse model of Alzheimer's disease.
Maurice T, Mustafa MH, Desrumaux C, Keller E, Naert G, de la C García-Barceló M, Rodríguez Cruz Y, Garcia Rodríguez JC. Maurice T, et al. Among authors: garcia rodriguez jc. J Psychopharmacol. 2013 Nov;27(11):1044-57. doi: 10.1177/0269881113494939. Epub 2013 Jun 26. J Psychopharmacol. 2013. PMID: 23813967
18 results